Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 6/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23530859 | 0.88 | PDE10A (0.34) | KLKB1GAAMAPK1MAPTSMN1; SMN2 | |
| SCHEMBL23530871 | 0.86 | RAB9A (0.39) | KLKB1RAB9AGAAMAPK1MAPT | |
| SCHEMBL23530794 | 0.83 | RAB9A (0.48) | KLKB1RAB9AGAAMAPTSMN1; SMN2 | |
| SCHEMBL23530758 | 0.81 | HSD17B10 (0.47) | RAB9AMAPK1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL20838999 | 0.78 | ALDH1A1 (0.46) | RAB9AGAAMAPK1MEN1KMT2A | |
| SCHEMBL23531003 | 0.77 | KLKB1 (0.40) | KLKB1MAPTKDM4EPOLBALDH1A1 | |
| SCHEMBL23530864 | 0.76 | RAB9A (0.39) | KLKB1RAB9AGAAMAPK1MAPT | |
| SCHEMBL20838997 | 0.76 | ROCK2 (0.40) | KLKB1MAPK1 | |
| SCHEMBL23530583 | 0.76 | KLKB1 (0.43) | KLKB1 | |
| SCHEMBL23530958 | 0.75 | KLKB1 (0.35) | KLKB1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144197-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2023-05-11 | — | — | US | disclosed |
| WO-2021122745-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144197-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | CDK1, CDK3, CDK2 | KLKB1 2395/4885RAB9A 2672/4885GAA 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.